TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04969315: TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

Sponsor: Portage Biotech · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 35 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT04969315 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04969315 Rescue Dossier →